title: A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.
authors.affiliation: Clinical Oncology Department, A Coruña University Hospital, A Coruña, Spain.
authors.forename: Ana Milena
authors.initials: AM
authors.lastname: Roldán
authors.forename: Natalia Fernández
authors.initials: NF
authors.lastname: Núñez
authors.forename: Enrique
authors.initials: E
authors.lastname: Grande
authors.forename: Augusto Álvarez
authors.initials: AÁ
authors.lastname: García
authors.forename: Luis M
authors.initials: LM
authors.lastname: Antón-Aparicio
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D018279:Carcinoma, Signet Ring Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D000068818:Cetuximab; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil